Back to search

Zomagen Biosciences Ltd

11475190

active
Private Limited Company
england wales
Companies House
Health Score
65 / 100

Some Concerns

25/30
Filing
0/30
Financial
40/40
Risk
  • No accounts filed in last 18 months (-5)
  • Negative net worth (-10)
  • Current liabilities exceed current assets (-10)
  • Going concern doubt noted in accounts (-10)

Details

5 NEW STREET SQUARE, LONDON, EC4A 3TW
Incorporated 20/07/2018

Compliance

Last accounts

31/12/2024

small

Next accounts due

30/09/2026

On track

Confirmation statement

Last: 19/07/2025

Due 02/08/2026

On track

Industry

72110
Research and experimental development on biotechnology

Officers

John Nuss

director · Since 17/04/2024

PHARMA RESEARCH AND DEVELOPMENT

AMERICAN · UNITED STATES · Age 67

Christopher Stokes

director · Since 31/03/2026

AMERICAN · UNITED KINGDOM · Age 47

Also on 1 other board

Kristina Mignon Wright

director · Since 31/03/2026

AMERICAN · UNITED KINGDOM · Age 47

Also on 10 other boards

Persons with Significant Control

Raju Mohan

25–50% shares
25–50% votes

American · United States · Age 69

5, New Street Square, London, EC4A 3TW

Notified 20/07/2018

Former PSCs

Somasundaram Subramaniam

Ceased 01/04/2020

CompanyRankvs 29190+ SIC 72110 peers
25

Financial strength0th percentile among SIC peers · 0/25
Employees65th percentile among SIC peers · 10/15
LiquidityCurrent ratio 0.08× · 2/20
Longevity8 years trading (max 15) · 8/15
Filing complianceAll filings up to date · 15/15
Going concern doubt -10
Show leaderboard
1Werfen Limited
90
2Biopharma Process Systems Limited
90
3Theradex (Europe) Limited
90
4Spicer Consulting Limited
90
5Exmoor Pharma Concepts Limited
90
6Ubc Late Stage (Uk) Limited
90
7Wuxi Apptec Uk Ltd
90
8Labgenius Limited
89
9Nuclera Ltd
88
10Aparito Limited
87
2919Zomagen Biosciences Ltd
35
How is this score calculated?
Financial strength0/25 pts

Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.

Employees10/15 pts

Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.

Liquidity2/20 pts

Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.

Longevity8/15 pts

One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.

Filing compliance15/15 pts

Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.

Risk deductions

Going concern doubt: -10 pts

Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.

Going Concern Doubt

that the existing financial support from Ventyx Biosciences were to change, Zomagen Biosciences Limited may not remain a going concern. The directors do not believe this to be a likely scenario. On this basis, the directors of Zomagen Biosciences Limited have concluded that there are no material uncertainties that may cast doubt on

Key FinancialsYear ending 31/12/2023

Net Worth

-£50.3M

Balance sheet strength

Cash

£807k

Cash in the bank

Net Current Assets

-£50.4M

Working capital

Current Assets

£4.3M

Current Liabilities

£54.7M

Fixed Assets

£87k

Debtors

£4.3M

Profit After Tax

-£23.9M

2avg. employees

Balance Sheet

Assets less current liabilities-£50.3M
Prepared with Caseware UK (AP4) 2023.0.135

EstimatesDerived

YearCurrent Ratio
20230.08

Derived from filed accounts. Not audited figures.